» Articles » PMID: 30696910

Imaging Endogenous Macrophage Iron Deposits Reveals a Metabolic Biomarker of Polarized Tumor Macrophage Infiltration and Response to CSF1R Breast Cancer Immunotherapy

Overview
Journal Sci Rep
Specialty Science
Date 2019 Jan 31
PMID 30696910
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Iron deposits are a phenotypic trait of tumor-associated macrophages (TAMs). Histological iron imaging and contrast-agent free magnetic resonance imaging (MRI) can detect these deposits, but their presence  in human cancer, and correlation with immunotherapeutic response is largely untested. Here, primarily using these iron imaging approaches, we evaluated the spatial distribution of polarized macrophage populations containing high endogenous levels of iron in preclinical murine models and human breast cancer, and used them as metabolic biomarkers to correlate TAM infiltration with response to immunotherapy in preclinical trials. Macrophage-targeted inhibition of the colony stimulating factor 1 receptor (CSF1R) by immunotherapy was confirmed to inhibit macrophage accumulation and slow mammary tumor growth in mouse models while also reducing hemosiderin iron-laden TAM accumulation as measured by both iron histology and in vivo iron MRI (FeMRI). Spatial profiling of TAM iron deposit infiltration defined regions of maximal accumulation and response to the CSF1R inhibitor, and revealed differences between microenvironments of human cancer according to levels of polarized macrophage iron accumulation in stromal margins. We therefore demonstrate that iron deposition serves as an endogenous metabolic imaging biomarker of TAM infiltration in breast cancer that has high translational potential for evaluation of immunotherapeutic response.

Citing Articles

New Insights into Aspirin's Anticancer Activity: The Predominant Role of Its Iron-Chelating Antioxidant Metabolites.

Kontoghiorghes G Antioxidants (Basel). 2025; 14(1).

PMID: 39857363 PMC: 11763074. DOI: 10.3390/antiox14010029.


Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy.

Zivalj M, Van Ginderachter J, Stijlemans B Cancers (Basel). 2023; 15(21).

PMID: 37958332 PMC: 10648573. DOI: 10.3390/cancers15215159.


Targeting iron to contrast cancer progression.

Tomat E Curr Opin Chem Biol. 2023; 74:102315.

PMID: 37187095 PMC: 10225354. DOI: 10.1016/j.cbpa.2023.102315.


Control of tumor-associated macrophage responses by nutrient acquisition and metabolism.

Zhang X, Ji L, Li M Immunity. 2023; 56(1):14-31.

PMID: 36630912 PMC: 9839308. DOI: 10.1016/j.immuni.2022.12.003.


New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer.

Kontoghiorghes G Int J Mol Sci. 2022; 23(22).

PMID: 36430469 PMC: 9696688. DOI: 10.3390/ijms232213990.


References
1.
Lin E, Nguyen A, Russell R, Pollard J . Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193(6):727-40. PMC: 2193412. DOI: 10.1084/jem.193.6.727. View

2.
Le N, Richardson D . The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002; 1603(1):31-46. DOI: 10.1016/s0304-419x(02)00068-9. View

3.
Lin E, Jones J, Li P, Zhu L, Whitney K, Muller W . Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003; 163(5):2113-26. PMC: 1892434. DOI: 10.1016/S0002-9440(10)63568-7. View

4.
Zakian K, Shukla-Dave A, Meyers P, Gorlick R, Healey J, Thaler H . Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 2003; 63(24):9042-7. View

5.
Pollard J . Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1):71-8. DOI: 10.1038/nrc1256. View